Articles
Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
Alterations of voluntary behavior in the course of disease progress and pharmacotherapy in mice with collagen-induced arthritis
Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
No hay comentarios:
Publicar un comentario